Pharming Group to participate in February investor conference
February 10, 2025 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, February 10, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
February 07, 2025 16:00 ET
|
Pharming Group N.V.
This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to...
Pharming Group to convene Extraordinary General Meeting of Shareholders
January 21, 2025 12:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will hold an Extraordinary General Meeting of...
Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer
January 21, 2025 01:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has nominated Fabrice...
Pharming announces public cash offer to the shareholders of Abliva AB
December 15, 2024 13:45 ET
|
Pharming Group N.V.
Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset Abliva’s lead product KL1333 is currently in a pivotal clinical trial, with a positive interim...
Pharming announces positive topline data in pediatric clinical trial of leniolisib
December 11, 2024 01:00 ET
|
Pharming Group N.V.
Multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Data consistent with the improvements seen in the previously...
Pharming Group to participate in November investor conference
November 05, 2024 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, November 5, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group reports third quarter 2024 financial results and provides business update
October 24, 2024 01:00 ET
|
Pharming Group N.V.
Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023, driven by continued strong RUCONEST® and Joenja® revenue growthRUCONEST® third quarter...
Pharming Group to report third quarter 2024 financial results on October 24
October 10, 2024 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2024 financial...
Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
October 10, 2024 01:00 ET
|
Pharming Group N.V.
Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes PIDs to include ALPS-FAS, CTLA4 haploinsufficiency, NFKB1...